CTRCD is prevalent in patients with non-high-risk breast cancer undergoing trastuzumab chemotherapy. Low- and moderate-risk patients show distinct responses to trastuzumab. The LV-GLS is the only deformation index sensitive to early trastuzumab-related cardiac dysfunction.
Keyphrases
- left ventricular
- epidermal growth factor receptor
- metastatic breast cancer
- end stage renal disease
- ejection fraction
- oxidative stress
- newly diagnosed
- chronic kidney disease
- heart failure
- prognostic factors
- acute myocardial infarction
- tyrosine kinase
- peritoneal dialysis
- hypertrophic cardiomyopathy
- aortic stenosis
- cardiac resynchronization therapy
- high intensity
- patient reported outcomes
- cross sectional
- aortic valve
- breast cancer risk